RWOD: Redwoods Acquisition Corp. Stock

by  •  • Comments Off on RWOD: Redwoods Acquisition Corp. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 36.10
Enterprise Value ($M) 37.54
Book Value ($M) -7.35
Book Value / Share -1.42
Price / Book -4.91
NCAV ($M) -26.61
NCAV / Share -5.15
Price / NCAV -1.36

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) 0.01
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.09
Current Ratio 0.09

Balance Sheet (mrq) ($M)
Current Assets 0.20
Assets 19.46
Liabilities 26.81
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -1.30
Net Income 1.35
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -1.26
Cash from Investing 101.91
Cash from Financing -100.82

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-22 13G/A Shaolin Capital Management LLC 0.00 -100.00
02-13 13G/A MMCAP International Inc. SPC 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-17 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-11-17 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-10-18 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPO
2023-08-21 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-24 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 2,114 9,027 23.42
2024-05-02 4,539 15,883 28.58
2024-05-01 3,656 14,750 24.79
2024-04-30 13,114 2,624 499.77
2024-04-29 16,033 5,645 284.02

(click for more detail)

Similar Companies
RNAC – Cartesian Therapeutics, Inc. RPHM – Reneo Pharmaceuticals, Inc.
RVNC – Revance Therapeutics, Inc. RYTM – Rhythm Pharmaceuticals, Inc.
SAGE – Sage Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io